IQVIA HOLDINGS INC

NYSE: IQV (IQVIA Holdings, Inc.)

Last update: 08 Aug, 4:51AM

178.95

1.46 (0.82%)

  • 1D 0.82%
  • 5D -3.72%
  • 1M 12.58%
  • 6M -8.94%
  • YTD -8.29%
  • 1Y -26.39%
  • 5Y 11.73%
Previous Close 177.49
Open 179.83
Volume 1,028,825
Avg. Volume (3M) 2,418,453
Market Cap 30,421,499,904
Price / Earnings (TTM) 25.90
Price / Earnings (Forward) 15.17
Price / Sales 2.04
Price / Book 5.27
52 Weeks Range
134.65 (-24%) — 252.88 (41%)
Earnings Date 22 Jul 2025
Profit Margin 7.88%
Operating Margin (TTM) 13.39%
Diluted EPS (TTM) 6.89
Quarterly Revenue Growth (YOY) 5.30%
Quarterly Earnings Growth (YOY) -26.70%
Total Debt/Equity (MRQ) 272.12%
Current Ratio (MRQ) 0.840
Operating Cash Flow (TTM) 2.62 B
Levered Free Cash Flow (TTM) 2.45 B
Return on Assets (TTM) 5.16%
Return on Equity (TTM) 19.79%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Mixed
Diagnostics & Research (Global) Mixed Mixed
Stock IQVIA Holdings, Inc. Bullish Bearish

AIStockmoo Score

0.3
Analyst Consensus 1.5
Insider Activity -1.5
Price Volatility 1.0
Technical Moving Averages 0.0
Technical Oscillators 0.5
Average 0.30

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
IQV 30 B - 25.90 5.27
A 29 B 0.71% 23.50 5.28
MTD 24 B - 28.57 -
WAT 21 B - 31.93 8.04
RVTY 11 B 0.23% 38.54 1.39
DHR 143 B 0.43% 38.60 2.89

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Sector Healthcare
Industry Diagnostics & Research
Investment Style Mid Core
% Held by Insiders 1.05%
% Held by Institutions 98.21%

Ownership

Name Date Shares Held
Farallon Capital Management Llc 31 Mar 2025 3,411,851
Longview Partners (Guernsey) Ltd 31 Mar 2025 2,028,276
52 Weeks Range
134.65 (-24%) — 252.88 (41%)
Price Target Range
177.00 (-1%) — 235.00 (31%)
High 235.00 (Truist Securities, 31.32%) Buy
Median 196.00 (9.53%)
Low 177.00 (JP Morgan, -1.09%) Buy
Average 203.29 (13.60%)
Total 5 Buy, 2 Hold
Avg. Price @ Call 183.10
Firm Date Target Price Call Price @ Call
Mizuho 25 Jul 2025 225.00 (25.73%) Buy 199.17
Baird 23 Jul 2025 196.00 (9.53%) Hold 194.24
Barclays 23 Jul 2025 185.00 (3.38%) Hold 194.24
Truist Securities 23 Jul 2025 235.00 (31.32%) Buy 194.24
UBS 23 Jul 2025 225.00 (25.73%) Buy 194.24
Evercore ISI Group 09 Jul 2025 180.00 (0.59%) Buy 162.02
JP Morgan 19 May 2025 177.00 (-1.09%) Buy 143.54

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria